UCB: positive phase 3 results in lupus

(CercleFinance.com) - UCB and Biogen announced at the American College of Rheumatology meeting in Washington, D.
C., positive detailed results from the Phase 3 PHOENYCS GO study evaluating their dapirolizumab pegol (DZP) in moderate to severe systemic lupus erythematosus (SLE).

This new drug candidate met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity.

They add that a greater response was observed to several clinical endpoints in participants treated with DZP, including 50% fewer severe disease flares compared to participants on standard treatment alone.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.